Chronic obstructive pulmonary disease and comorbidity
DOI:
https://doi.org/10.19230/jonnpr.3863Keywords:
chronic obstructive pulmonary disease, Comorbidities, treatmentsAbstract
Introduction. Chronic obstructive pulmonary disease (COPD) is one of the diseases with the highest prevalence and mortality rates worldwide. In Spain, it is the third leading cause of death. Tobacco is its main risk factor, so it is a preventable disease. We can define it as a complex and heterogeneous syndrome that conditions both quality of life and the aging of those who suffer from it, especially in the last decades of life, since it is accompanied by a not inconsiderable number of comorbidities that aggravate the evolution of the it.
Objectives. To understand the most prevalent comorbidities in COPD, as well as their relationship and possible influence on the progress of the disease.
Material and methods. Bibliographic search in Pubmed and Cochrane using the terms "chronic obstructive pulmonary disease" AND "comorbidities", applying different filters during the search.
Results: The presence of comorbidity affects short and long term mortality. The relationship between comorbidity and COPD can be explained by the existence of systemic inflammation.
Discussion. There is enough evidence to affirm that the presence of comorbidity is an unfavourable fact in terms of the evolution of the patient with COPD.
Conclusions. A multidimensional assessment of the COPD patient is necessary, as well as comprehensive and individualized care.
Downloads
References
OMS | Enfermedad pulmonar obstructiva crónica (EPOC) [Internet]. [2020]. Disponible en: https://www.who.int/respiratory/copd/es/
«EPI-Scan 2»: el primer mapa completo de la EPOC en España [Internet]. Redacción Médica. [2020]. Disponible en: https://www.redaccionmedica.com/secciones/neumologia/-epi-scan-2-el-primer-mapacompleto-de-la-epoc- en-espana-4123
INE: Datos de causas de muerte año 2018 [Internet]. Tableau Software. [2020]. Disponible en:
https://public.tableau.com/views/CAUSASDEMUERTE1/Dashboard1?:showVizHome=no&:embed=true
Defunciones por causas (lista reducida) por sexo y grupos de edad(7947) [Internet]. INE. [2020]. Disponible en: https://www.ine.es/jaxiT3/Datos.htm?t=7947#!tabs-grafico
Importancia de los síntomas en la EPOC [Internet]. [2020]. Disponible en: http://scielo.isciii.es/scielo.php? script=sci_arttext&pid=S1131-57682003000300006
Definición, etiología, factores de riesgo y fenotipos de la EPOC. Arch Bronconeumol. 2017;53:5-11.
Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, et al. Guía española de la enfermedad pulmonar obstructiva crónica (GesEPOC) 2017. Tratamiento farmacológico en fase estable. Arch Bronconeumol. 2017;53(6):324-35.
Alfageme I, de Lucas P, Ancochea J, Miravitlles M, Soler-Cataluña JJ, García-Río F, et al. Nuevo estudio sobre la prevalencia de la EPOC en España: resumen del protocolo EPISCAN II, 10 años después de EPISCAN. Archivos de Bronconeumología. 2019;55(1):38-47.
Almagro P, Cabrera FJ, Diez J, Boixeda R, Alonso Ortiz MB, Murio C, et al. Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the EPOC en Servicios de medicina interna (ESMI) study. Chest. 2012;142(5):1126-33.
Boixeda R, Díez-Manglano J, Gómez-Antúnez M, López-García F, Recio J, Almagro P. Consensus for managing patients with chronic obstructive pulmonary disease according to the CODEX index. Rev Clin Esp. 2019;219(9):494-504.
de Miguel Díez J, García TG, Maestu LP. [Comorbidities in COPD]. Arch Bronconeumol. d 2010;46 Suppl 11:20- 5.
Rabinovich RA, MacNee W. Chronic obstructive pulmonary disease and its comorbidities. Br J Hosp Med (Lond).;72(3):137-45.
Díez Manglano J, Bernabeu-Wittel M, Escalera-Zalvide A, Sánchez-Ledesma M, Mora-Rufete A, Nieto-Martín D, et al. Comorbilidad, discapacidad y mortalidad en pacientes pluripatológicos con enfermedad pulmonar obstructiva crónica. Revista Clínica Española. 2011;211(10):504-10.
Díez-Manglano J, Recio Iglesias J, Varela Aguilar JM, Almagro Mena P, Zubillaga Garmendia G, los investigadores del estudio COREPOC, en nombre del grupo de EPOC de la Sociedad Española de Medicina Interna. Effectiveness of a simple intervention on management of acute exacerbations of chronic obstructive pulmonary disease and its cardiovascular comorbidities: COREPOC study. Med Clin (Barc). 2017;149(6):240-7.
Leone N, Courbon D, Thomas F, Bean K, Jégo B, Leynaert B, et al. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. Am J Respir Crit Care Med. 2009;179(6):509-16.
Alonso I, Luis J. Comorbilidades de la enfermedad pulmonar obstructiva crónica. Arch Bronconeumol. 2016;52(11):547-8.
Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5(4):549-55.
Carrasco Sánchez FJ, Iglesias JR, Amorós JG. Tratamiento complementario de la insuficiencia cardíaca aguda en el paciente con diabetes, enfermedad pulmonar obstructiva crónica o anemia. Medicina Clínica. 2014;142:59- 65.
Patel ARC, Donaldson GC, Mackay AJ, Wedzicha JA, Hurst JR. The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. Chest. 2012;141(4):851-7.
Portillo Carroz K. La anemia en la EPOC. ¿Debemos pensar en ello? Arch Bronconeumol. 2007;43(7):392-8.
Hacia un tratamiento individualizado e integrado del paciente con EPOC | Archivos de Bronconeumología [Internet]. [2020]. Disponible en: https://www.archbronconeumol.org/es-hacia-un-tratamiento-individualizado- e-articulo-S030028961070051X
EPOC y alteraciones endocrinometabólicas | Archivos de Bronconeumología [Internet]. [2020]. Disponible en: https://www.archbronconeumol.org/es-epoc-alteracionesendocrinometabolicas-articulo-S0300289609728637
EPOC e inflamación sistémica. Una vía de enlace para la comorbilidad | Archivos de Bronconeumología [Internet]. [2020]. Disponible en: http://archbronconeumol.org/esepoc-e-inflamacin-sistmica-una-articulo- resumen-S0300289609728583
Núñez B, Sauleda J, Garcia-Aymerich J, Noguera A, Monsó E, Gómez F, et al. Ausencia de correlación entre marcadores de inflamación pulmonar y sistémica en pacientes con enfermedad pulmonar obstructiva crónica: un análisis bi-compartimental simultáneo. Arch Bronconeumol. 2016;52(7):361-7.
Calle Rubio M, Rodríguez Hermosa JL, Soler-Cataluña JJ, López-Campos JL, Alcazar Navarrete B, Soriano JB, et al. Atención médica según el nivel de riesgo y su adecuación a las recomendaciones de la guía española de la enfermedad pulmonar obstructiva crónica (EPOC) (GesEPOC): Estudio EPOCONSUL. Arch Bronconeumol. 2018;54(5):270-9.
Llauger Roselló MA, Pou MA, Domínguez L, Freixas M, Valverde P, Valero C. Atención a la EPOC en el abordaje al paciente crónico en atención primaria. Arch Bronconeumol. 2011;47(11):561-70.
Cataluña JJS, García MÁM. Comorbilidad cardiovascular en la EPOC. Arch Bronconeumol. 2009;45:18-23.
Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155-61.
Calverley Pm, Anderson Ja, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol y propionato de fluticasona y supervivencia en la enfermedad pulmonar obstructiva crónica. N Engl J Med 2007; 356 (8): 775–89.
Roberto A. Rabinovich , Zafeiris Louvaris , Yogini Raste , Daniel Langer , Hans Van Remoortel , Santiago Giavedoni , Chris Burtin , Eloisa MG Regueiro , Ioannis Vogiatzis , Nicholas S. Hopkinson , Michael I. Polkey , Frederick J. Wilson , William MacNee , Klaas R. Westerterp , Thierry Troosters en nombre del consorcio PROactive. Validez de los monitores de actividad física durante la vida diaria en pacientes con EPOC. European Respiratory Journal 2013 42: 1205-1215; DOI:10.1183 /09031936.00134312.
Bartolomé R. Celli , Alvar Agustí. EPOC: ¿hora de mejorar su taxonomía?. ERJ Open Research 2018 4: 00132- 2017; DOI:10.1183 / 23120541.00132-2017
Published
Issue
Section
License
All accepted originals remain the property of JONNPR. In the event of publication, the authors exclusively transfer their rights of reproduction, distribution, translation and public communication (by any sound, audiovisual or electronic medium or format) of their work. To do so, the authors shall sign a letter transferring these rights when sending the paper via the online manuscript management system.
The articles published in the journal are freely used under the terms of the Creative Commons BY NC SA license, therefore.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
